SRT2104, a mechanistically similar compound that also increases sirt1 activity, has reached clinical trials for the treatment of diabetes (NCT01018017), ulcerative colitis (NCT01453491), and immobilization‐induced muscle atrophy (NCT01039909). Here, SIRT1 is linked to diabetes mellitus.